Metraipolis › archive › dc_7bb3814d451d

Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review — Europe PMC PMID:41715239

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41715239
DOI: 10.1186/s40842-[numero omesso]-4
License (as archived): solo-consultazione
Archived: 2026-11-05T14:53:26.089Z
SHA-256 of the archived text: 68e3cef110851c4f904e2385c05646c4573d84a92d21e8339f53eec3b7743938
Stable URL of this page: https://metraipolis.com/documento/dc_7bb3814d451d

How to cite

Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review — Europe PMC PMID:41715239 — Europe PMC (en), https://europepmc.org/article/MED/41715239 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7bb3814d451d (Metraipolis archive dc_7bb3814d451d, sha256 68e3cef110851c4f904e2385c05646c4573d84a92d21e8339f53eec3b7743938)

BibTeX

@misc{dc7bb3814d451d,
  title = {Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review — Europe PMC PMID:41715239},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41715239},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7bb3814d451d; sha256 68e3cef110851c4f904e2385c05646c4573d84a92d21e8339f53eec3b7743938},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41715239. Agents can read the archived copy with the MCP tool read_document.